Aims Glucocorticoids suppress the release of tumour necrosis factor-a (TNF-a) by macrophages in vitro and cause monocytopaenia in vivo. These actions may contribute to anti-inflammatory and immunosuppressant effects. We therefore examined relationships between prednisolone concentration, suppression of monocyte TNF-a release, monocytopaenia and suppression of total cortisol concentration in healthy volunteers treated with a single dose (1.5 mg kg −1 ) of the glucocorticoid, prednisolone.
Introduction experimentally [9, 10] . If similar actions occur during human therapy, they may contribute to the anti-inflammatory The monokine tumour necrosis factor-a (TNF-a) contributes to the pathogenesis of endotoxic shock, rheumatoid efficacy of glucocorticoids. Indeed, the concentrations measurable in blood during therapy with the glucocorticoid, arthritis, multiple sclerosis and other inflammatory diseases [1] [2] [3] . Glucocorticoids are effective anti-inflammatory and prednisolone, can reach the level which would be expected to suppress monokine production in vitro [11] . However, immunosuppressive agents, with actions on most cells involved in inflammatory or immune responses [4] . In vitro, whereas the free concentration of prednisolone would be expected to approximate the total concentration under glucocorticoids suppress release of TNF-a and a wide range of other monocyte/macrophage activities [5] [6] [7] [8] . Glucoexperimental conditions, the free fraction of prednisolone in blood is concentration-dependent and may be only 5% of corticoids also provide relative protection from lethality in experimental endotoxaemia, suggesting capacity to suppress the total [11, 12] . This may be insufficient for a clinicallyrelevant effect on TNF-a release. Furthermore, prednisolone concentrations decline rapidly after a conventional oral dose, [11, 13] . There is no information on the duration of release with the glucocorticoid antagonist, mifepristone and by determining whether the relationship between prednisomonocyte/macrophage response after transient exposure to glucocorticoids and, therefore, no means to predict whether lone concentrations in the blood of the volunteers and TNF-a suppression could be reproduced by adding prednisoany effects of glucocorticoids in vivo would persist as the drug was eliminated. Together, these factors may partially lone in known concentration to blood taken from the same volunteers when they were drug-free. explain the failure of glucocorticoids to influence the outcome of other conditions in which TNF-a has a role in pathogenesis, including human endotoxic shock [14] and the failure of glucocorticoids to reproduce in vivo some Methods monocyte effects which are demonstrable in vitro [15] .
Nonetheless, glucocorticoids are effective in suppressing Sampling procedure inflammatory activity in rheumatoid arthritis and multiple sclerosis, where TNF-a also contributes importantly to A single oral dose of prednisolone of approximately 1.5 mg kg −1 was administered to eight healthy, fasting pathogenesis [16, 17] . Additionally, relatively small doses of glucocorticoids (comparable with doses which are effective volunteers (20-42 years, two female) as tablets (Fawns & McAllan, Victoria, Australia). Blood samples were collected in rheumatoid arthritis) are sufficient for negative effects on some non-monocytic cells, the most notable effects being before dosing and at 2, 4, 8, 12, 24 and 48 h post-dose into EDTA-and heparin-treated evacuated tubes (Venoject@). suppressed secretion of hypothalamic corticotropin-releasing hormone (CRH) and suppressed expression of the pro-EDTA-anticoagulated blood was used for automated differential white cell counts by a Coulter STKS Analyser opiomelanocortin (POMC) gene and its product, adrenocorticotropic hormone (ACTH) by the pituitary gland [18] . [26] and heparinised blood was used for measurement of plasma cortisol and prednisolone by h.p.l.c. (see below). The result is suppression of the hypothalamic-pituitaryadrenal axis (HPA) axis, with diminished production of
Separated heparinised plasma was also tested for capacity to suppress monocyte TNF-a production (see below). endogenous cortisol. Therapeutic concentrations of glucocorticoids are known also to affect at least one monocyte Two weeks later, a further 70 ml blood sample was collected into heparinised tubes, pooled and then divided function in vivo, that is, the number of monocytes in peripheral blood [19] . A decline in blood monocyte count into aliquots of 3.5 ml. Each aliquot was centrifuged and 1.3 ml of plasma was removed and replaced with the same occurs during conventional therapy. This decline makes it difficult to interpret the glucocorticoid-induced reduction volume of plasma from one of the samples collected in the first 48 h. Each 3.5 ml sample then yielded triplicate samples in circulating TNF-a reported in blood of volunteers treated with lipopolysaccharide (LPS) [20] . of 1 ml each in 24 well cell culture plates (Costar). This procedure ensured that equal numbers of autologous We therefore administered single doses of prednisolone of 1.5 mg kg −1 to healthy volunteers and observed the monocytes were present with each of the original plasma samples, a condition which could not be achieved using the extent and duration of glucocorticoid-mediated suppression of TNF-a release from peripheral blood monocytes. An ex original, unseparated whole blood samples because of prednisolone-induced changes in monocyte numbers. The vivo whole blood incubation method was used to avoid the administration of toxic agents (such as LPS) to human concentrations of cortisol and prednisolone in the 1.3 ml of plasma added to the samples had been measured by h.p.l.c. volunteers and to avoid the confusing influence of changing monocyte numbers in LPS-treated and prednisolone-treated and therefore were known. The original volume of plasma in the samples was calculated from the haematocrit, allowing human subjects. The intensity and duration of monocytopaenia after prednisolone administration provided an additional an estimate of the total prednisolone concentration in the reconstituted samples. The calculation disregards the small in vivo index of monocyte response and this was compared with the intensity and duration of suppressed plasma cortisol amount of free prednisolone which equilibrates with erythrocyte contents [27] . Reconstituted whole blood concentration. Finally, glucocorticoids act on many cell types to alter release of products which potentially modify samples were stimulated with 0.1 mg ml
serotype 026-B6; Sigma), added 30 min after reconstitution. monocyte/macrophage functions. The POMC gene products ACTH [21] , b-endorphin [22] and a-melanocyte Additional triplets were prepared using plasma from the final sample and were not stimulated with LPS, to indicate stimulating hormone (a-MSH) [23] all modulate the activity of monocyte/macrophages experimentally, as do CRH and baseline, unstimulated TNF-a production. Samples were then incubated for 4 h at 37°C and 5% CO 2 , as previously somatostatin [24, 25] . These are principally products of neuroendocrine tissue, but inflammatory cells have also been described [28] . Plasma was re-separated by centrifugation and TNF-a was measured by sandwich enzyme-linked shown to release CRH and somatostatin and to express the POMC gene [23, 25] . CRH secretion and POMC gene immunosorbent assay, as previously described [29, 30] . Recombinant human TNF-a, a gift from Dr G.R. Adolf expression are glucocorticoid-sensitive in neuroendocrine tissue, at least [18] , whilst somatostatin release from (Boehringer, Ingelheim), served as standard. Samples were diluted 10 fold in RPMI medium for assay and standards inflammatory tissue may also be glucocorticoid-sensitive [25] . It is therefore possible that the observed effects of were likewise reconstituted in RPMI medium containing 10% normal human serum. All additives used in the prednisolone on monocyte TNF-a release were not direct, but were secondary to a glucocorticoid-induced change in procedure were checked for endotoxin contamination using the Limulus amebocyte lysate test (BioWhittaker Inc, non-monocytic tissue. This possibility was examined by attempting to reverse the observed suppression of TNF-a Walkersville, MD) and rejected if endotoxin concentration exceeded 0.1 u ml −1 . All glassware was baked prior to use monocyte count and LPS-stimulated TNF-a release were made using Dunnett's test. Prednisolone concentration-time and all plastic-ware was new.
Additional incubates were prepared from the 4 h specidata was fitted to a single compartment pharmacokinetic model incorporating first-order absorption and elimination mens (seven subjects) or 8 h specimen (one subject) and were treated with mifepristone (RU 486: Roussel-Uclaf ) at processes, using a non-linear least-squares fitting procedure (TopFit 2.0) [32] . 50 mm, to seek evidence that suppression of TNF-a production was due to glucocorticoid present in the sample. This was further investigated by attempting to reproduce Results the observed relationship between prednisolone concentration and TNF-a suppression by adding prednisolone in Prednisolone, cortisol and monocyte kinetics known concentration to blood taken from the same volunteers when they were drug-free. A further set of
The highest prednisolone concentration (854±49 ng ml −1 ) was in the 2 h sample in all volunteers. The mean elimination incubates was therefore prepared in the same way from each volunteer's final blood sample, except that the plasma was half-life estimated by pharmacokinetic modelling was 3.15 h (Figure 1 ). The mean cortisol concentration before dosing derived from the same sample (i.e. removed by centrifugation and then returned) and prednisolone (Sigma) was added was 134±42 ng ml −1 and was suppressed by 83% at 2 h.
The 95% CI for the mean difference was 46 to 175 ng ml −1 . to concentrations of 1.8×10 4 ng ml −1 (50 mm), 1.8× 10 3 ng ml −1 (5 mm), 360 ng ml −1 (1 mm) and 36 ng ml
By 8 h, cortisol was unmeasurable in plasma in three of the (0.1 mm). LPS was introduced 30 min later and incubation proceeded, as above. The relationship between prednisolone concentration and suppression of LPS-stimulated TNF-a release in these samples was compared with the relationship apparent from studies of the samples taken in the 48 h after the dose. Studies on human volunteers were approved by the Human Rights Committee of the University of Western Australia and each participant provided written consent.
Glucocorticoid assays
Prednisolone and cortisol were measured in plasma by h.p.l.c., using a LC5000 pump, an AS2000 automatic injector (both from ICI Instruments, Melbourne, Australia) and a SP1500 integrator (Spectral Physics, CA). The mobile phase was prepared by mixing dichloromethane (AR grade, Merck), ethanol (AR grade, Merck) and water (175151). The resultant organic phase was separated and 1% glacial acetic acid was added. Flow rate was 1 ml min −1
. A Porosil 30 cm×4 mm column (10 mm; Waters Instruments) was used for normal-phase separation and glucocorticoids were quantitated by absorbance at 254 nm, using a Waters 484 Tunable Absorbance Detector. Dexamethasone (250 ng in ethanol; Sigma) was added to each sample as internal standard. Standards for cortisol and prednisolone (Sigma) were prepared in charcoal-stripped plasma of a normal donor [31] . Samples and standards (1 ml) were extracted sequentially with 8 ml hexane (AR Grade, Merck) and then with 8 ml dichloromethane. The dichloromethane was washed with 1 ml of 0.1 m NaOH followed by 1 ml of distilled water before being separated and evaporation under a nitrogen stream. The resultant extract was dissolved in 100 ml mobile phase and 50 ml was injected. Assay sensitivities were 10 ng ml −1 for cortisol and prednisolone.
Time after dose (h) sample (control) for plasma cortisol, plasma prednisolone, volunteers (limit of detection: 10 ng ml −1 ). Cortisol concentrations at 24 h (40±11 ng ml −1 ) remained significantly lower than pre-dose, despite the absence of measurable prednisolone in five subjects (limit of detection: 10 ng ml −1 ). The 95% CI for the mean difference was 28
to 168 ng ml −1 . Cortisol concentrations recovered to predose levels at 48 h ( Figure 1 ). The predose blood monocyte count in the volunteers was 0.57±0.03×10 9 l −1 . Monocyte numbers fell to a mean of 18% of pre-dose levels at 8 h. The 95% CI for the mean difference was 0.34×10 9 l −1 to 0.48×10 9 l −1
. Partial recovery occurred by 12 h and a rebound monocytosis occurred at 24 h in all volunteers (P<0.05, compared to pre-dose level; 95% CI for the mean difference of 0.15×10 9 l −1 to 0.33×10 9 l −1 ). Monocyte numbers had returned to pre-dose levels at 48 h ( Figure 1 ). Similar variations were seen in lymphocyte numbers in all volunteers (Figure 1) . In contrast the number of polymorphonuclear leukocytes significantly exceeded baseline (3.2±0.23×10 9 l −1 ) at between 2 h and 24 h, with a peak at 4 h of 7.6±0.67×10 9 l −1 .
Ex vivo release of TNF-a by whole blood
Whole blood samples reconstituted with pre-dose plasma concentrations of prednisolone therein (Figures 1 and 2) . (95% CI for the mean difference was 4.3 to 6.1 ng ml −1 ) **P<0.05, compared with 4 h value in absence of mifepristone and 28% (95% CI for the mean difference was 4.1 to (n=7).
6.1 ng ml −1 ) by the 2 h and 4 h plasma samples, respectively.
Concentrations of TNF-a in the LPS-stimulated 24 and 48 h samples did not differ significantly from the pre-dose 95% CI for the mean of the difference between prednisolone (1 mm)-treated and control samples was 4.13 to samples. The glucocorticoid antagonist, mifepristone (50 mm) alone did not lead to release of TNF-a from unstimulated 6.82 ng ml −1 . A relationship between the concentration of added prednisolone and TNF-a suppression was apparent. blood samples. Rather, it slightly suppressed LPS stimulated release from the final blood sample (2 weeks) from This was very similar to the relationship between measured prednisolone concentrations and suppression of TNF-a 7.7±0.86 ng ml −1 to 7.3±0.77 ng ml −1 in the absence of prednisolone (P=0.03, Paired t-test). However, treatment release in post-dose plasma samples (Figure 3) . Additional blood samples were collected from one of the reconstituted 4 h sample with 50 mm mifepristone restored mean LPS-stimulated TNF-a levels to 72% of the volunteer before the dose and at 24 h. They were stimulated with LPS immediately after collection and without separapre-dose sample (seven subjects). The 95% CI for the mean difference between mifepristone-treated and untreated tion, to find out whether monocytes had recovered capacity for TNF-a release at 24 h after prednisolone exposure in samples was 0.22 to 3.44 ng ml −1 . Mifepristone treatment of the 8 h sample from the eighth volunteer restored release vivo. TNF-a release from the pre-dose sample was 7.8 ng ml −1 , corresponding to 13 ng 10 6 cells
, whilst the to 93%.
Prednisolone, added to whole blood samples collected release at 24 h was 14.1 ng ml −1 , corresponding to 17.6 ng 10 6 cells −1 and indicating complete recovery. after the complete elimination of the dose (2 weeks), suppressed TNF-a production in a concentration-dependent manner in each of the volunteers. Measurable TNF-a was Discussion not released in the absence of LPS. The concentration of TNF-a in LPS-stimulated samples, in the absence of added For at least 8 h after a single oral dose of 1.5 mg kg −1 , prednisolone is present in plasma in concentrations and prednisolone, was 7.7±0.86 ng ml −1 . Although volunteers varied in their response to LPS, the relative suppression of forms which are sufficient to suppress release of TNF-a by monocytes. At 24 h, monocyte numbers and capacity for TNF-a release by prednisolone was very similar for all. At 1 mm added prednisolone, mean LPS-stimulated TNF-a TNF-a release have recovered but hypocortisolaemia persists. Together, these observations imply that prednisolone actions production was 27% of production by control samples. The Figure 3 Blood samples were collected from the eight volunteers when they were drug-free. Prednisolone was added to samples at known concentrations and they were stimulated with LPS, as described in methods. The relationship between concentrations of added prednisolone and LPS-stimulated TNF-a in whole blood samples of eight volunteers is shown in (a) (mean±s.e.mean). This is compared with the relationship between measured prednisolone and TNF-a in whole blood reconstituted with plasma collected after oral dosing with prednisolone in the same subjects (b). The eight subjects are each represented by a different plot. Each point represents the measured prednisolone and TNF-a concentrations at one time point, in one subject. Two samples from each volunteer (pre-dose and 48 h) and 24 h samples from three volunteers contained no measurable prednisolone. The TNF-a values at zero prednisolone concentration are the means of the levels in these samples for each subject.
on blood monocytes are relatively short-lived compared in the transactivation of the TNF-a gene [36] . The interactions between glucocorticoids, mifepristone, AP-1 with effects on the HPA axis. Blood monocytes are constantly replenished from precursors in bone marrow and the TNF-a promoter have yet to be investigated. The effects of prednisolone were concentration-dependent and possibly contributing to more rapid recovery [33] . Plasma cortisol concentrations recover abruptly after suppression, were very similar for orally-administered prednisolone and for prednisolone added after blood was collected. Again, this reflecting the pulsatile nature of secretion [11] . This would have occurred at some time between 24 and 48 h in these indicates that the actions of prednisolone are likely to be direct. volunteers. Differences in the duration of glucocorticoids action on target and other tissues would be important Prednisolone induced profound, but transient, monocytopaenia. Glucocorticoids reduce the bone marrow production determinants of the balance between efficacy and toxicity.
The partial reversal by mifepristone of TNF-a suppression of monocytes by approximately 20% in mice [19, 37] . However, the mean transit time of monocytes in the human in 4 h specimens confirms that the action of prednisolone is mostly direct and not through some glucocorticoid-induced circulation has been estimated as 36 to 104 h [38], so monocytopaenia develops more rapidly than can be modification of other circulating plasma components such as ACTH [21] , b-endorphin [22] , a-MSH [23], CRH or explained by cessation of monocyte release from bone marrow alone. The findings of this and previous studies [37] somatostatin [24, 25] . Mifepristone incompletely reversed the prednisolone effect, possibly because concentrations imply that monocytes leave circulating blood at an accelerated rate. The site of redistribution has not been defined. were insufficient to completely antagonise the high concentrations of prednisolone present at the time, or possibly Lymphopaenia and recovery, which occurred synchronously with monocytopaenia and recovery in these studies are because mifepristone acts as a partial glucocorticoid agonist under some circumstances [34] . Mifepristone caused a small, understood to result from redistribution of lymphocytes between blood and other body compartments, particularly but significant, suppression of LPS-stimulated TNF-a release in prednisolone-free samples, suggesting that it acts as a the bone marrow [39, 40] . Studies in mice have shown that glucocorticoids reduce, rather than increase, the egress of partial glucocorticoid agonist at this relatively high concentration (50 mm) and under these conditions. Mifepristone monocytes into the peritoneum, but egress into bone marrow has not been examined [37] . The monocytes may behaves as a glucocorticoid agonist in respect of the negative regulation of AP-1-mediated transactivation of the colnot, in fact, leave the blood. It has been estimated that approximately 75% of monocytes in human blood are lagenase gene, at least [35] , and AP-1 appears to be important monocytes and endothelial cells. The glucocorticoid, predny-
